JP2013544835A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013544835A5 JP2013544835A5 JP2013542030A JP2013542030A JP2013544835A5 JP 2013544835 A5 JP2013544835 A5 JP 2013544835A5 JP 2013542030 A JP2013542030 A JP 2013542030A JP 2013542030 A JP2013542030 A JP 2013542030A JP 2013544835 A5 JP2013544835 A5 JP 2013544835A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- methyl
- salt
- cancer
- oxazolo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 14
- 150000003839 salts Chemical class 0.000 claims 14
- 239000011780 sodium chloride Substances 0.000 claims 14
- 125000004215 2,4-difluorophenyl group Chemical group [H]C1=C([H])C(*)=C(F)C([H])=C1F 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 5
- -1 3-methyloxetane-3-yl Chemical group 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 3
- 125000004938 5-pyridyl group Chemical group N1=CC=CC(=C1)* 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 2
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Substances CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 201000009251 multiple myeloma Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 238000000634 powder X-ray diffraction Methods 0.000 claims 2
- ICSNLGPSRYBMBD-UHFFFAOYSA-N 2-Aminopyridine Chemical compound NC1=CC=CC=N1 ICSNLGPSRYBMBD-UHFFFAOYSA-N 0.000 claims 1
- XOTBZLSRXJRYJS-ZDUSSCGKSA-N 2-[4-(2,4-difluorophenyl)-5-[2-[[(2S)-4-methoxybutan-2-yl]amino]-[1,3]oxazolo[5,4-b]pyridin-5-yl]-1H-imidazol-2-yl]-2-methylpropan-1-ol Chemical compound N1=C2OC(N[C@@H](C)CCOC)=NC2=CC=C1C=1N=C(C(C)(C)CO)NC=1C1=CC=C(F)C=C1F XOTBZLSRXJRYJS-ZDUSSCGKSA-N 0.000 claims 1
- 239000002147 L01XE04 - Sunitinib Substances 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- WINHZLLDWRZWRT-ATVHPVEESA-N Sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 claims 1
- YSQNOJMVGVZJRJ-UHFFFAOYSA-N [1,3]oxazolo[5,4-b]pyridin-2-amine Chemical compound C1=CN=C2OC(N)=NC2=C1 YSQNOJMVGVZJRJ-UHFFFAOYSA-N 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000005745 ethoxymethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])* 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- XOBKSJJDNFUZPF-UHFFFAOYSA-N methoxyethyl Chemical group CCOC XOBKSJJDNFUZPF-UHFFFAOYSA-N 0.000 claims 1
- 229960001796 sunitinib Drugs 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Claims (17)
- 2−[5−(2,4−ジフルオロフェニル)−4−[2−[[(1S)−3−メトキシ−1−メチル−プロピル]アミノ]オキサゾロ[5,4−b]ピリジン−5−イル]−1H−イミダゾール−2−イル]−2−メチル−プロパン−1−オールである請求項1に記載の化合物、又はその薬学的に許容し得る塩。
- 15.06におけるピーク、並びに19.94、10.31及び20.78(2θ+/−0.2°)における1以上のピークを含むX線粉末回折パターン(Cu放射、λ=1.54060Å)を特徴とする結晶質の2−[5−(2,4−ジフルオロフェニル)−4−[2−[[(1S)−3−メトキシ−1−メチル−プロピル]アミノ]オキサゾロ[5,4−b]ピリジン−5−イル]−1H−イミダゾール−2−イル]−2−メチル−プロパン−1−オールである、請求項1又は請求項2に記載の化合物。
- 13.73におけるピーク、並びに16.54、22.87及び18.57(2θ+/−0.2°)における1以上のピークを含むX線粉末回折パターン(Cu放射、λ=1.54060Å)を特徴とする結晶質の2−[5−(2,4−ジフルオロフェニル)−4−[2−[[(1S)−3−メトキシ−1−メチル−プロピル]アミノ]オキサゾロ[5,4−b]ピリジン−5−イル]−1H−イミダゾール−2−イル]−2−メチル−プロパン−1−オールである、請求項1又は請求項2に記載の化合物。
- 5−[2−シクロプロピル−5−(2,4−ジフルオロフェニル)−1H−イミダゾール−4−イル]−N−[(1S)−3−メトキシ−1−メチル−プロピル]オキサゾロ[5,4−b]ピリジン−2−アミンである、請求項1に記載の化合物、又はその薬学的に許容し得る塩。
- 5−[5−(2,4−ジフルオロフェニル)−2−(3−メチルオキセタン−3−イル)−1H−イミダゾール−4−イル]−N−[(1S)−3−メトキシ−1−メチル−プロピル]オキサゾロ[5,4−b]ピリジン−2−アミンである、請求項1に記載の化合物、又はその薬学的に許容し得る塩。
- [1−[5−(2,4−ジフルオロフェニル)−4−[2−[[(1S)−2−エトキシ−1−メチル−エチル]アミノ]オキサゾロ[5,4−b]ピリジン−5−イル]−1H−イミダゾール−2−イル]シクロプロピル]メタノールである、請求項1に記載の化合物、又はその薬学的に許容し得る塩。
- 1以上の薬学的に許容し得る担体、希釈剤、又は賦形剤と組み合わせて、請求項1〜7のいずれか一項に記載の化合物又は塩を含む医薬組成物。
- 1以上の治療剤を更に含む、請求項8に記載の医薬組成物。
- 治療において使用するための請求項1〜7のいずれか一項に記載の化合物又は塩。
- 癌の治療において使用するための請求項1〜7のいずれか一項に記載の化合物又は塩。
- 前記癌が、卵巣癌である、請求項11に記載の使用のための化合物又は塩。
- 前記癌が、多発性骨髄腫である、請求項11に記載の使用のための化合物又は塩。
- 癌の治療においてスニチニブと同時に、別々に、又は順次組合せて使用するための請求項1〜7のいずれか一項に記載の化合物又は塩。
- 前記癌が、腎臓癌である、請求項14に記載の使用のための化合物又は塩。
- 卵巣癌を治療するための医薬の製造における請求項1〜7のいずれか一項に記載の化合物または塩の使用。
- 多発性骨髄腫を治療するための医薬の製造における請求項1〜7のいずれか一項に記載の化合物または塩の使用。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10382329.0 | 2010-12-03 | ||
EP10382329 | 2010-12-03 | ||
US201161439151P | 2011-02-03 | 2011-02-03 | |
US61/439,151 | 2011-02-03 | ||
PCT/US2011/061099 WO2012074761A1 (en) | 2010-12-03 | 2011-11-17 | Oxazolo [5, 4 -b] pyridin- 5 -yl compounds and their use for the treatment of cancer |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2013544835A JP2013544835A (ja) | 2013-12-19 |
JP2013544835A5 true JP2013544835A5 (ja) | 2014-07-03 |
JP5726321B2 JP5726321B2 (ja) | 2015-05-27 |
Family
ID=46162794
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013542030A Expired - Fee Related JP5726321B2 (ja) | 2010-12-03 | 2011-11-17 | オキサゾロ[5,4−b]ピリジン−5−イル化合物および癌治療へのその使用 |
Country Status (26)
Country | Link |
---|---|
US (1) | US8288548B2 (ja) |
EP (1) | EP2646445B1 (ja) |
JP (1) | JP5726321B2 (ja) |
KR (1) | KR101514162B1 (ja) |
CN (1) | CN103221415B (ja) |
AR (1) | AR083868A1 (ja) |
AU (1) | AU2011337033A1 (ja) |
BR (1) | BR112013013282A2 (ja) |
CA (1) | CA2819822C (ja) |
CL (1) | CL2013001518A1 (ja) |
CO (1) | CO6761387A2 (ja) |
CR (1) | CR20130182A (ja) |
DO (1) | DOP2013000116A (ja) |
EA (1) | EA021241B1 (ja) |
EC (1) | ECSP13012653A (ja) |
ES (1) | ES2567271T3 (ja) |
GT (1) | GT201300139A (ja) |
IL (1) | IL226054A0 (ja) |
MX (1) | MX2013006184A (ja) |
NZ (1) | NZ610289A (ja) |
PE (1) | PE20140008A1 (ja) |
SG (1) | SG190680A1 (ja) |
TW (1) | TWI410425B (ja) |
UA (1) | UA109677C2 (ja) |
WO (1) | WO2012074761A1 (ja) |
ZA (1) | ZA201303580B (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102279347B1 (ko) | 2016-12-15 | 2021-07-21 | 한국생명공학연구원 | 피리딘계 화합물을 유효성분으로 함유하는 dyrk 관련 질환의 예방 또는 치료용 약학적 조성물 |
CN114748622A (zh) | 2017-10-05 | 2022-07-15 | 弗尔康医疗公司 | P38激酶抑制剂降低dux4和下游基因表达以用于治疗fshd |
US10342786B2 (en) | 2017-10-05 | 2019-07-09 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ520640A (en) | 2000-02-15 | 2005-04-29 | Upjohn Co | Pyrrole substituted 2-indolinone protein kinase inhibitors |
AR029803A1 (es) * | 2000-02-21 | 2003-07-16 | Smithkline Beecham Plc | Imidazoles sustituidos con piridilo y composiciones farmaceuticas que las comprenden |
DE60207390T2 (de) * | 2001-03-09 | 2006-07-20 | Pfizer Products Inc., Groton | Entzündungshemmende benzimidazolverbindungen |
ES2274302T3 (es) * | 2002-08-09 | 2007-05-16 | Eli Lilly And Company | Benzimidazoles y benzotiazoles como inhibidores de la map quinasa. |
TWI332003B (en) * | 2004-01-30 | 2010-10-21 | Lilly Co Eli | Kinase inhibitors |
EP1781293A1 (en) | 2004-06-04 | 2007-05-09 | Amphora Discovery Corporation | Quinoline- and isoquinoline-based compounds exhibiting atp-utilizing enzyme inhibitory activity, and compositions, and uses thereof |
US7723340B2 (en) | 2005-01-13 | 2010-05-25 | Signal Pharmaceuticals, Llc | Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith |
US7473784B2 (en) * | 2005-08-01 | 2009-01-06 | Bristol-Myers Squibb Company | Benzothiazole and azabenzothiazole compounds useful as kinase inhibitors |
PE20091008A1 (es) * | 2007-08-02 | 2009-08-10 | Amgen Inc | Derivados heterociclicos como moduladores de fosfoinositida 3-cinasa |
-
2011
- 2011-11-14 AR ARP110104244A patent/AR083868A1/es unknown
- 2011-11-14 TW TW100141464A patent/TWI410425B/zh not_active IP Right Cessation
- 2011-11-17 BR BR112013013282A patent/BR112013013282A2/pt not_active IP Right Cessation
- 2011-11-17 CA CA2819822A patent/CA2819822C/en not_active Expired - Fee Related
- 2011-11-17 UA UAA201306158A patent/UA109677C2/ru unknown
- 2011-11-17 PE PE2013001339A patent/PE20140008A1/es not_active Application Discontinuation
- 2011-11-17 MX MX2013006184A patent/MX2013006184A/es not_active Application Discontinuation
- 2011-11-17 JP JP2013542030A patent/JP5726321B2/ja not_active Expired - Fee Related
- 2011-11-17 SG SG2013034749A patent/SG190680A1/en unknown
- 2011-11-17 CN CN201180058009.2A patent/CN103221415B/zh not_active Expired - Fee Related
- 2011-11-17 NZ NZ610289A patent/NZ610289A/en not_active IP Right Cessation
- 2011-11-17 KR KR1020137014068A patent/KR101514162B1/ko not_active IP Right Cessation
- 2011-11-17 ES ES11791146.1T patent/ES2567271T3/es active Active
- 2011-11-17 EP EP11791146.1A patent/EP2646445B1/en not_active Not-in-force
- 2011-11-17 WO PCT/US2011/061099 patent/WO2012074761A1/en active Application Filing
- 2011-11-17 EA EA201390620A patent/EA021241B1/ru not_active IP Right Cessation
- 2011-11-17 AU AU2011337033A patent/AU2011337033A1/en not_active Abandoned
- 2011-11-17 US US13/298,319 patent/US8288548B2/en not_active Expired - Fee Related
-
2013
- 2013-04-25 CR CR20130182A patent/CR20130182A/es unknown
- 2013-04-29 IL IL226054A patent/IL226054A0/en unknown
- 2013-05-16 ZA ZA2013/03580A patent/ZA201303580B/en unknown
- 2013-05-27 DO DO2013000116A patent/DOP2013000116A/es unknown
- 2013-05-28 GT GT201300139A patent/GT201300139A/es unknown
- 2013-05-29 CL CL2013001518A patent/CL2013001518A1/es unknown
- 2013-05-31 EC ECSP13012653 patent/ECSP13012653A/es unknown
- 2013-06-11 CO CO13139854A patent/CO6761387A2/es active IP Right Grant
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2016501221A5 (ja) | ||
RU2012138892A (ru) | СОЛИ И ПОЛИМОРФЫ 8-ФТОР-2-{4-[(МЕТИЛАМИНО)МЕТИЛ]ФЕНИЛ}-1,3,4,5,-ТЕТРАГИДРО-6Н-АЗЕПИНО[5,4,3-cd]ИНДОЛ-6-ОНА | |
JP2016516043A5 (ja) | ||
JP2016522835A5 (ja) | ||
JP2016520116A5 (ja) | ||
JP2014518266A5 (ja) | ||
JP2012524731A5 (ja) | ||
JP2010525056A5 (ja) | ||
JP2012153722A5 (ja) | ||
JP2011529054A5 (ja) | ||
JP2013510124A5 (ja) | ||
JP2011509949A5 (ja) | ||
EP2620432A3 (en) | Diarylhydantoin compounds | |
JP2013508382A5 (ja) | ||
JP2013522326A5 (ja) | ||
RU2014120792A (ru) | Способ лечения стромальных опухолей желудочно-кишечного тракта | |
RU2015125307A (ru) | Комбинированная терапия | |
JP2014526549A5 (ja) | ||
JP2012533546A5 (ja) | ||
JP2010241830A5 (ja) | ||
TWI455939B (zh) | cMET抑制劑 | |
HRP20192101T1 (hr) | Inhibitori ezh2 | |
JP2013542261A5 (ja) | ||
JP2011088926A5 (ja) | ||
JP2010536842A5 (ja) |